452 related articles for article (PubMed ID: 36974474)
21. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
22. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
[TBL] [Abstract][Full Text] [Related]
23. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
24. Current approach to treatments for prolactinomas.
Tirosh A; Shimon I
Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
[TBL] [Abstract][Full Text] [Related]
25. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
26. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
28. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
29. Hyperprolactinemia and prolactinomas.
Mancini T; Casanueva FF; Giustina A
Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
[TBL] [Abstract][Full Text] [Related]
30. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Prolactinoma.
Inder WJ; Jang C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
[TBL] [Abstract][Full Text] [Related]
32. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
33. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
35. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.
Fleseriu M; Lee M; Pineyro MM; Skugor M; Reddy SK; Siraj ES; Hamrahian AH
J Neurooncol; 2006 Aug; 79(1):41-3. PubMed ID: 16598425
[TBL] [Abstract][Full Text] [Related]
36. Prolactinomas in children and adolescents--consequences in adult life.
Duntas LH
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
[TBL] [Abstract][Full Text] [Related]
37. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
38. Italian Guidelines for the Management of Prolactinomas.
Cozzi R; Simona Auriemma R; De Menis E; Esposito F; Ferrante E; Iatì G; Mazzatenta D; Poggi M; Rudà R; Tortora F; Cruciani F; Mitrova Z; Saulle R; Vecchi S; Basile M; Cappabianca P; Paoletta A; Papini E; Persichetti A; Samperi I; Scoppola A; Bozzao A; Caputo M; Doglietto F; Ferraù F; Lania AG; Laureti S; Lello S; Locatelli D; Maffei P; Minniti G; Peri A; Ruini C; Settanni F; Silvani A; Veronese N; Grimaldi F; Attanasio R
Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1459-1479. PubMed ID: 37171003
[TBL] [Abstract][Full Text] [Related]
39. 2012 update in the treatment of prolactinomas.
Maiter D; Primeau V
Ann Endocrinol (Paris); 2012 Apr; 73(2):90-8. PubMed ID: 22503806
[TBL] [Abstract][Full Text] [Related]
40. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
Chanson P; Maiter D
Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
